Efficacy News and Research

RSS

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.

6 Apr 2013

India's Supreme Court ruling on drug patent will promote affordable medicines, 'preserve' innovation incentives

Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."

6 Apr 2013

Individualized genomic analysis allows for tailored cancer treatment, new drug research

Just like a massive iceberg jutting out of the ocean, many of cancer's genetic underpinnings remain hidden under the surface, impossible to predict or map from above.

6 Apr 2013

Writing therapy is an evidence-based treatment for PTS, says study

This study demonstrates that writing therapy resulted in significant and substantial short-term reductions in post traumatic symptoms (PTS) and comorbid depressive symptoms.

5 Apr 2013

Research: Hepatitis A virus steals membranes from infected cells to protect it from antibodies

Viruses have historically been classified into one of two types - those with an outer lipid-containing envelope and those without an envelope.

5 Apr 2013

Emergent BioSolutions provides update on TRU-016 Phase 1b study

Emergent BioSolutions Inc. today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia.

5 Apr 2013

UIC College of Pharmacy receives grant to train students in natural product drugs

Elizabeth Martinez hopes to one day discover a cure for menopausal symptoms using an herbal dietary supplement. With the help of a new federal training grant to the University of Illinois at Chicago College of Pharmacy, her vision may become reality.

5 Apr 2013

BioInvent International presents clinical results of BI-505 at myeloma workshop in Kyoto

BioInvent International AB announce that the previously communicated positive results from a phase I trial of BI-505 is presented today at The International Myeloma Workshop in Kyoto, Japan.

4 Apr 2013

Scientists develop a new way to generate induced pluripotent stem cell lines from human fibroblasts

A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.

4 Apr 2013

Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up.

4 Apr 2013

FDA clears ERYTECH Pharma' IND to start Phase I clinical trial of ERYASP in patients with ALL

ERYTECH Pharma SA announced today that it has received clearance of its Investigational New Drug Application from the United States Food and Drug Administration to initiate a Phase I clinical trial of its product ERYASP, L-asparaginase loaded erythrocytes, in patients 40 years or older with newly diagnosed Acute Lymphoblastic Leukemia.

4 Apr 2013

Study: V710 vaccine does not reduce postoperative Staphylococcus aureus infections

Use of a vaccine to prevent Staphylococcus aureus infections among patients undergoing cardiothoracic surgery did not reduce the rate of serious postoperative S aureus infections compared with placebo and was associated with increased mortality among patients who developed S aureus infections, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Polymer scaffolds can advance the development of cancer therapeutics

Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.

3 Apr 2013

Researchers at UC Davis MIND Institute to establish Autism Center of Excellence and Treatment Network

Autism researchers at the UC Davis MIND Institute have received a prestigious $13 million award from the National Institutes of Health to establish an Autism Center of Excellence and Treatment Network, making the MIND Institute one of only nine such centers in the United States.

3 Apr 2013

Biogen acquires TYSABRI stake from Elan

Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.

3 Apr 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

A team of UC Davis scientists has found that a product resulting from a metabolized omega-3 fatty acid helps combat cancer by cutting off the supply of oxygen and nutrients that fuel tumor growth and spread of the disease.

3 Apr 2013

Discovery of new signalling pathway creates hope for hormone therapy resistance

A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant.

2 Apr 2013

Microbiology testing services now offered by Ceram

Ceram, the international materials testing and development company, has announced that it is now offering microbiology testing services for the healthcare industries, thanks to a partnership with a leading UK microbiological testing lab.

2 Apr 2013

New born neurons as a therapeutic strategy: an interview with Mi-Hyeon Jang, Mayo Clinic in Rochester, Minnesota

There are two regions in the brain that continue to produce new neurons well into adulthood. One of these regions is the hippocampus and as we converse this region is actively involved in memory formation, mood regulation and cognition.

2 Apr 2013

Efficacy News and Research

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

India's Supreme Court ruling on drug patent will promote affordable medicines, 'preserve' innovation incentives

Individualized genomic analysis allows for tailored cancer treatment, new drug research

Writing therapy is an evidence-based treatment for PTS, says study

Research: Hepatitis A virus steals membranes from infected cells to protect it from antibodies

Emergent BioSolutions provides update on TRU-016 Phase 1b study

UIC College of Pharmacy receives grant to train students in natural product drugs

BioInvent International presents clinical results of BI-505 at myeloma workshop in Kyoto

Scientists develop a new way to generate induced pluripotent stem cell lines from human fibroblasts

Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

FDA clears ERYTECH Pharma' IND to start Phase I clinical trial of ERYASP in patients with ALL

Study: V710 vaccine does not reduce postoperative Staphylococcus aureus infections

Polymer scaffolds can advance the development of cancer therapeutics

Researchers at UC Davis MIND Institute to establish Autism Center of Excellence and Treatment Network

Biogen acquires TYSABRI stake from Elan

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

Discovery of new signalling pathway creates hope for hormone therapy resistance

Microbiology testing services now offered by Ceram

New born neurons as a therapeutic strategy: an interview with Mi-Hyeon Jang, Mayo Clinic in Rochester, Minnesota

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News